Health

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data.

Original Source

Publication Date: 
06/10/2017
Selidji T. Agnandji, José F. Fernandes, Emmanuel B. Bache & et al
PLoS Medicine
1-26
Tags:
Ebola Virus Disease (Ebola Hemorrhagic Fever), Gabon, Africa, Vector Borne Diseases, Drugs, Medical Research